A randomized blinded dose–response human biomarker study of remote ischemic conditioning
Brain Circulation · 2026-10 · 12 (4) · 389-395
DOI: 10.4103/bc.bc_42_25 ↗Abstract
Abstract: BACKGROUND: Remote ischemic conditioning (RIC) is emerging as a simple, inexpensive, and safe intervention for improving systemic vascular health in addition to standard treatments. It involves intermittent ischemic compressions of limbs. RIC mechanisms and optimal therapeutic protocols remain to be established. METHODS: We conducted a RIC dose–response randomized blinded study in patients following a mild stroke or transient ischemic attack. Patients were randomly allocated into five dose groups, including sham, within 6 months of their qualifying event. RIC was applied for 28 days followed by 7 days off period. Weekly blood biomarkers tested included red blood cell (RBC) deformability, RBC nitric oxide synthase, adenosine monophosphate kinase, and the inflammasome NLRP3, and macrophage TNF-α and IL-10. The primary outcome was change in the biomarkers over time and was examined using mixed models adjusting for A1c. RESULTS: Forty participants, eight per group, completed this study. There were no significant changes over time between groups in any of the biomarkers tested (all P > 0.07). In addition, biomarker changes from baseline to end of the 4-week treatment were not significantly different between groups (all P > 0.10). CONCLUSIONS: The biomarkers tested in this study did not have a clear dose response effect from RIC. Other biomarkers may prove useful in monitoring the effects of RIC. TRIAL REGISTRATION: https://clinicaltrials.gov (identifier: 1513705-3).
EUVIMED